Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2016 - 2025)

Catalyst Pharmaceuticals' Total Non-Current Liabilities history spans 14 years, with the latest figure at $149.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 21.09% year-over-year to $149.5 million; the TTM value through Dec 2025 reached $149.5 million, up 21.09%, while the annual FY2025 figure was $149.5 million, 21.09% up from the prior year.
  • Total Non-Current Liabilities reached $149.5 million in Q4 2025 per CPRX's latest filing, up from $131.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $149.5 million in Q4 2025 to a low of $31.0 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $87.8 million, with a median of $82.7 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 97.52% in 2022, then increased 21.09% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $31.0 million in 2021, then surged by 97.52% to $61.1 million in 2022, then increased by 29.61% to $79.3 million in 2023, then soared by 55.79% to $123.5 million in 2024, then grew by 21.09% to $149.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Total Non-Current Liabilities are $149.5 million (Q4 2025), $131.2 million (Q3 2025), and $115.6 million (Q2 2025).